您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > NOD-IN-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
NOD-IN-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
NOD-IN-1图片
CAS NO:132819-92-2
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
NOD-IN-1 is a novel and potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors with IC50 of 5.74 μM and 6.45 μM for NOD1 and NOD2, respectively. It displayed a balanced inhibitory activity on both targets in the low micromolar range. NOD1 and NOD2 are important members of the pattern recognition receptor family and play a crucial role within the context of innate immunity. However, overactivation of NODs, especially of NOD1, has also been implicated in a number of diseases. Surprisingly, NOD1 remains a virtually unexploited target in this respect.
理化性质和储存条件
Molecular Weight (MW) 343.40
Formula C18H17NO4S
CAS No. 132819-92-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 10 mM
Water: <1 mg/mL
Ethanol: <1 mg/mL
Chemical Name Ethyl 1-tosyl-1H-indole-2-carboxylate
Synonyms NOD-IN-1; NOD-IN1; NOD-IN 1
SMILES Code O=C(C(N1S(=O)(C2=CC=C(C)C=C2)=O)=CC3=C1C=CC=C3)OCC
实验参考方法
In Vitro

In vitro activity: NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively. NOD1 and NOD2 are important members of the pattern recognition receptor family and play a crucial role within the context of innate immunity. However, overactivation of NODs, especially of NOD1, has also been implicated in a number of diseases. Surprisingly, NOD1 remains a virtually unexploited target in this respect.


Kinase Assay: NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively.


Cell Assay: HEK-Blue NOD1 and NOD2 cells (Invivogen) were cultured in DMEM medium (Sigma) with 10 % heat-deactivated FBS (Gibco), 2 mM l-glutamine (Sigma), 50 U/mL penicillin (Sigma), 50 ng/mL streptomycin (Sigma), 4.5 g glucose (Sigma) and 100 μg/mL Normocin (Invivogen) for 2 passages. All subsequent passages were cultured in the medium supplemented with 30 μg/mL Blasticidin (Invivogen) and 100 μg/mL Zeocin (Invivogen). The experiments were carried out on passages 7–12. NOD-IN-1 (compound 4) is potent mixed inhibitor of NOD1 and NOD2, displaying a balanced inhibitory activity on both targets in the low micromolar range. NOD-IN-1 (IC50 (NOD1)=5.74 μM; IC50 (NOD2)=6.45 μM) is identified as the best of the series, possessing NOD1- and NOD2-inhibitory activities in the lower micromolar range. These results show that NOD-IN-1 is 7-fold less potent than Noditinib-1 in terms of NOD1 inhibition and completely devoid of selective activity for NOD1 or NOD2 as opposed to Noditinib-1. NOD-IN-1 exhibits balanced dual activities of less than 10 μM on the two targets.

In Vivo
Animal model
Formulation & Dosage
References Bioorg Med Chem. 2016 Nov 1;24(21):5221-5234.